Please add info@sitcancer.org to your safe senders list.
May 2016 – In this Issue
Cancer Immunotherapy Month Events | June Activity Details | SITC 2016
Social Media | Publications | Membership
A Message from the President
Dear Colleagues,
This is an exciting time in the field as we have seen significant scientific advances in tumor immunology, which has led directly to numerous new drug approvals over the last few years. As Vice President Joe Biden mentioned at a recent stakeholder discussion, we are at an inflection point in oncology with much progress but also considerable expectations. The path forward will depend on continued collaboration among scientists, clinicians, government officials and patient advocates. At this exciting time, it is also clear that cancer immunotherapy will be taking center stage in both national and international conversations.
Your dedication and hard work in the cancer immunotherapy field has made this all possible. In that spirit, we look forward to recognizing Cancer Immunotherapy Month with a number of educational events and activities throughout June culminating with the National Cancer Moonshot Summit on June 29, 2016.
The Society for Immunotherapy of Cancer (SITC) as an organization is dedicated to advancing the science and application of cancer immunotherapy and has long been innovators at the forefront of education in this space. Along with other SITC leadership, I have been pleased to participate in the Moonshot Initiative to represent our society. I think you will agree that we have many exciting events throughout June that reflect our commitment to providing top-level education for all stakeholders helping to position cancer immunotherapy as one of the four treatment modalities. Upcoming events include:
- Live educational programs for diverse audiences
- Fundraising and networking activities
- Opportunities for scientific collaboration
- SITC Moonshot Initiative event
- And more yet to be announced!
In this newsletter you will see the depth and breadth of the activities we have planned this month aimed at advancing our mission of improving patient outcomes and ultimately finding a cure. I look forward to celebrating Cancer Immunotherapy Month together.
Best regards,
Howard L. Kaufman, MD, FACS
SITC President
SITC Cancer Immunotherapy Month Events
We are looking forward to many events and activities as we approach Cancer Immunotherapy Month. These events will provide educational growth and professional development for healthcare providers, researchers and patients alike. We are excited to kick-off the month with a number of activities held during the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting June 3 - 7 in Chicago, Illinois. More details about these activities are provided later in this newsletter.
June 2 - 3, 2016
How to Integrate Tumor Immunotherapy into Your Clinical Practice
McCormick Place, S100bc • Chicago, Illinois
June 4 - 6, 2016
SITC Exhibit*
McCormick Place, Booth #25107 • Chicago, Illinois
June 5, 2016
Immunotherapy in Non-Small Cell Lung Cancer: Answering Clinically Relevant Questions*
6:00 - 8:30 pm • Sheraton Grand Chicago • Chicago, Illinois
The Future Is Now: The Evolution of Immunotherapy in Cancer*
6:00 - 8:30 pm • Sheraton Grand Chicago • Chicago, Illinois
Forward Fund – House of Blues Chicago Fundraiser*
8:00 pm - Midnight • House of Blues Chicago • Chicago, Illinois
“Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer:
Results of a worldwide consortium-based analysis of 1,336 patients.”
8:00 - 8:15 am • Hyatt Regency McCormick Place, Hall B1 • Chicago, Illinois
*Not an official event of the 2016 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation. Not CME-Accredited.
June 9, 2016
American Cancer Society Cancer Action Network Public Event
Immunotherapy: A New Frontier in Treating Cancer
7:30 - 9:30 am • Madison Club • Madison, Wisconsin
June 10 - 12, 2016
T Cell Based Immunotherapy: A Deeper Dive
Wailea Beach Marriott Resort & Spa • Wailea, Hawaii
June 12, 2016
CALL FOR COMMENT: Cancer Immunotherapy Guidelines for the Treatment of Renal
Cell Carcinoma
11:59 pm EST - Review period closes
June 14, 2016
Journal for ImmunoTherapy of Cancer (JITC) – June Issue
June 16 - 19, 2016
Regulatory Myeloid Suppressor Cells: From Basic Discovery to Application
The Wistar Institute • Philadelphia, Pennsylvania
June 17, 2016
White Out Cancer Day
Bridging the Gap Between Immunotherapy & Hypofractionated Radiation Therapy
7:30 - 11:15 am • Hilton Orlando • Orlando, Florida
June 23-24, 2016
Rational Combinations 360°
Park Lane Hotel • New York, New York
June 23, 2016
Advances in Cancer Immunotherapy™ – Cancer Immunotherapy 101
4:00 - 8:00 pm • Hyatt Regency McCormick Place • Chicago, Illinois
June 29, 2016
National Cancer Moonshot Summit
Howard University • Washington, DC
How to Integrate Tumor Immunotherapy into Your Clinical Practice
McCormick Place, S100bc
Chicago, Illinois • June 2 - 3, 2016
Strengthen your understanding of basic immunology and the management of patients receiving immunotherapy during this Pre-Annual Meeting Seminar presented by ASCO in collaboration with SITC. SITC members receive discounted registration; contact education@sitcancer.org for details. Find more information about this collaboration here.
SITC Exhibit*
McCormick Place, Booth #25107
Chicago, Illinois • June 4 - 6, 2016
Please visit our booth #25107 to say hello and learn about SITC offerings including membership, education programs, the Journal for ImmunoTherapy of Cancer and more. We look forward to seeing you!
Immunotherapy in Non-Small Cell Lung Cancer: Answering Clinically
Relevant Questions*
Sheraton Grand Chicago
Chicago, Illinois • June 5, 2016 • 6:00 - 8:30 pm
Presented by prIME Oncology in collaboration with SITC, this symposium, led by Roy S. Herbst, MD, PhD of the Yale Cancer Center, will present recent findings in clinical trials of immunotherapeutic agents for non-small cell lung cancer (NSCLC). Attendees will learn to translate these discoveries into clinical practice and monitor efficacy, recognize adverse events and apply methods to mitigate toxicity. Find more information about this collaboration with prIME Oncology and register for FREE here.
The Future Is Now: The Evolution of Immunotherapy in Cancer*
Sheraton Grand Chicago
Chicago, Illinois • June 5, 2016 • 6:00 - 8:30 pm
Examine the role of the immune system and the rationale for cancer immunotherapy as Leisha A. Emens, MD, PhD of Johns Hopkins University chairs this insightful symposium. Presented by prIME Oncology in collaboration with SITC, the symposium will explore immunotherapy in various solid tumor types and interactively discuss the results from ongoing clinical trials that continue the progression of these therapies into clinical practice. Find more information about this collaboration with prIME Oncology and register for FREE here.
Forward Fund – Fundraiser at the House of Blues Chicago
House of Blues Chicago
Chicago, Illinois • June 5, 2016 • 8:00 pm - Midnight
SITC invites you to celebrate the advances in cancer immunotherapy at the world famous House of Blues Chicago. Attendees will enjoy live music by SITC's own house band The CheckPoints! Reserve your limited availability presale, individual, and corporate VIP tickets online in advance here. For more details, contact the SITC Development Office at (414)-271-2456 or development@sitcancer.org. General admission tickets are only available at the door.
“Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients.”
Hyatt Regency McCormick Place, Hall B1
Chicago, Illinois • June 5, 2016 • 8:00 - 8:15 am
Initiated in 2012 with 23 centers and 17 countries worldwide, the SITC-led Immunoscore project aims to promote the use of the Immunoscore in routine clinical settings. Hear the results from the culmination of this remarkable initiative from the principal investigator of the study and SITC Board Member, Jérôme Galon, PhD. Learn more about this session and add it to your schedule here.
In order to help translate these exciting findings into the clinic and make them available to benefit patients, SITC is pleased to announce that key information from the Immunoscore project will be released prior to its publication. Please watch for an email in early June for more details and application instructions.
American Cancer Society Cancer Action Network Public Event
Immunotherapy: A New Frontier in Treating Cancer
Madison Club
Madison, Wisconsin • June 9, 2016 • 7:30 - 9:30 am
Leading experts will highlight the accomplishments and innovative strides of Wisconsin cancer researchers, feature their research and explore what immunotherapy could mean for the future of cancer care. Featured speakers include SITC leaders Paul M. Sondel, MD, PhD; Christian Capitini, MD; and Douglas G. McNeel, MD, PhD. For more details, or to purchase tickets, please contact Sara Sahli of the American Cancer Society Cancer Action Network at sara.sahli@cancer.org or 608-662-7557.
T Cell Based Immunotherapy: A Deeper Dive
Wailea Beach Marriott Resort & Spa
Wailea, Hawaii • June 10 - 12, 2016
This conference is your chance to meet some of the most accomplished scientists involved in understanding T cell function. Dissect the intricacies of T cell function in tumor-bearing hosts and join the discussion during a unique “think tank” format. Learn more and register here.
CALL FOR COMMENT:
Cancer Immunotherapy Guidelines for the Treatment of Renal Cell Carcinoma
June 12, 2016 • 11:59 pm EST - Review period closes
The SITC Cancer Immunotherapy Guidelines Task Force for Kidney Cancer has created guidelines to provide evidence-based consensus recommendations for the use of cancer immunotherapy in the clinical management of renal cell carcinoma. Because our membership is comprised of the world’s leading authority on cancer immunotherapy, we are seeking your feedback on this important manuscript before it is published. Open to SITC members only.
Your feedback on the development of this Consensus Statement is critical, as it provides an opportunity for the authors to review their recommendations. View this statement and submit your comments here.
Journal for ImmunoTherapy of Cancer (JITC)
June 14, 2016
As we look toward Cancer Immunotherapy Month, be sure to read to the June issue of JITC for commentaries on antitumor immune response with combination immunotherapy and immune-related response evaluations during immune-checkpoint inhibitor therapy.
Regulatory Myeloid Suppressor Cells: From Basic Discovery to Application
The Wistar Institute
Philadelphia, Pennsylvania • June 16 - 19, 2016
To further expand your understanding of the mechanisms regulating the accumulation of myeloid suppressor cells, SITC and The Wistar Institute are collaborating to provide these much anticipated scientific sessions and deep-diving discussions. Although registration is currently closed, you can be added to a waitlist by emailing your request to Catherine Michalski at cmichalski@wistar.org.
White Out Cancer Day
June 17, 2016
.png)
June 17th is White Out Cancer Day. Be sure to show your support by wearing white!
Join SITC in raising awareness of cancer immunotherapy by gathering friends, family, colleagues or students and wearing white on June 17. Take a selfie and share it on Twitter at @sitcancer using the hashtag #WhiteOutCancer or send it to us in an email and we'll post it for you.
Order a SITC CURE t-shirt here!
Proceeds from t-shirt sales go to the SITC Forward Fund.
Bridging the Gap Between Immunotherapy & Hypofractionated Radiation Therapy
Hilton Orlando
Orlando, Florida • June 17, 2016 • 7:30 - 11:15 am
This symposium will bring together clinicians and researchers with an interest in radiosurgery, radiotherapy and/or immunology to open a dialogue on the potential for exploiting radiation-induced immune responses in the context of cancer therapy. The symposium is a collaboration between the Radiosurgery Society (RSS), SITC, Radiation Research Society (RRS) and the National Cancer Institute (NCI). SITC board member Dr. Samir Khleif, MD will be one of two symposium moderators. Learn more and register here.
Rational Combinations 360°
Park Lane Hotel
New York, New York • June 23-24, 2016
With promising cancer immunotherapies in the clinic and an encouraging pipeline of new targets being developed, additional research is now under way to determine the most effective rational combinations that are personalized for individual patients and for specific tumors types. This program, a collaboration between The Conference Forum and SITC, will provide up-to-date information on combination developments that will aid in identifying the best cancer treatments for individual patients and tumor types. SITC members receive discounted registration; contact education@sitcancer.org for details. Learn more and register here.
Advances in Cancer Immunotherapy™ – Cancer Immunotherapy 101
Hyatt Regency McCormick Place
Chicago, Illinois • June 23, 2016 • 4:00 - 8:00 pm
This SITC CME- and CE-Certified regional program is specifically designed to teach the basic principles of tumor immunology and cancer immunotherapy, providing clinical teams with the foundation they need to care for their patients utilizing cancer immunotherapy. We look forward to your participation in this great opportunity to learn from and network with other professionals in your area. Learn more and register here.
National Cancer Moonshot Summit
Howard University
Washington, DC • June 29, 2016
On June 29, Vice President Biden will convene a first-of-its-kind summit focused on stimulating action and fostering collaborations around the goals of the National Cancer Moonshot – to make a decade’s worth of progress in preventing, diagnosing and treating cancer in just five years, and ultimately striving for a cure. Learn more here.
SITC 2016 Annual Meeting & Associate Programs Update
.jpg)
Value of Cancer Immunotherapy Summit
Gaylord National Hotel & Convention Center
National Harbor, Maryland • November 13, 2016 • 7:45 am - Noon
Presented by SITC in collaboration with ASCO, this summit will discuss the issues of value with respect to cancer immunotherapy, bringing a variety of different perspectives and experiences to the table. With key insights from researchers and clinicians to payers and patients, this summit will allow you to peer through different lenses when examining the full value of cancer immunotherapy. Don’t miss the opportunity to be a part of the discussion at SITC 2016. Register now!
Get More from SITC on Social Media
In the rapidly advancing field of cancer immunotherapy, it is essential to stay up-to-date on relevant topics and significant events. Join @sitcancer on Twitter as well as our LinkedIn group to be a part of the discussion.
Join in the conversation today!
JITC – The Resource for Cutting-Edge Science in the Field
Journal for ImmunoTherapy of Cancer (JITC) is SITC's official open access, peer-reviewed journal. It encompasses all aspects of tumor immunology and cancer immunotherapy, from basic research to clinical application. As the global voice of the society, JITC is the resource for SITC publications and also serves as a targeted outlet for publication of original research articles, literature reviews and position papers.
Interested in publishing in JITC? SITC members receive waived article processing charges for papers accepted through 2016. Submit your manuscript here.
First Clinical Trials Monitor Published
The newest journal section, Clinical Trials Monitor reports on important new trial results; updates on new drug approvals and ongoing clinical studies; key perspectives on clinical issues and advances in the field relevant to the everyday use of cancer immunotherapy in the clinic. This section also aims to address trial design and analysis considerations that may be unique to cancer immunotherapy, and to provide guidance for implementing and managing the use of cancer immunotherapies in the clinic.
The May 2016 issue marked the publication of the first Clinical Trials Monitor. Entitled “Harnessing autophagy to promote anti-tumor Immunity with the DRibbles vaccine,” by David Page and colleagues, this “Glimpse Into the Future” succinctly describes the pre-clinical rationale, translational data, and early clinical data pertaining to the DRibbles vaccine. This novel vaccine is produced by manipulating autophagy, and generates a multi-valent vaccine that could potentially induce tumor-specific immune responses against a variety of conventional tumor-associated antigens, as well as short-lived proteins and tumor-derived defective ribosomal products that would otherwise not be cross-presented under physiologic conditions. Please click here to read the article.
A SITC Membership Makes a Difference
SITC is the world’s leading member-driven society dedicated to professionals working in the field of cancer immunotherapy. As a member, you will join a growing network of nearly 1,300 basic and translational scientists, practitioners, healthcare professionals, government leaders and industry professionals worldwide. There are several membership categories. To learn more about how a SITC membership can make a difference for you, visit our membership page or call 414-271-2456.
Do You Love Being a Part of SITC? Connect-a-Colleague!
.png)
Encourage your colleagues including nurses, pharmacists and students, to become official SITC members by sending personalized invitations with our online tool or simply ask the people that you invite to list your name on their membership applications. Top referrers will receive recognition for their efforts.
ADVERTISEMENT
Society for Immunotherapy of Cancer (SITC)
555 East Wells Street, Suite 1100 | Milwaukee, Wisconsin 53202-3823 USA
Phone: +1 414 271 2456 | Email: info@sitcancer.org
© 2016 Society for Immunotherapy of Cancer
Join us on:
If you do not wish to be included in our mailing list, please forward this message to info@sitcancer.org with the word "Remove" in the subject line.
Please add info@sitcancer.org to your safe senders list.